Why Pfizer Stock is Worth Your Attention in 2024
Pfizer stock has undergone significant fluctuations in recent years, particularly after its remarkable performance during the pandemic. With the backdrop of its COVID-19 vaccine sales influencing much of its market behavior, the stock has now seen a substantial fall of over 60% since its highs of $61.71. Investors are now beginning to wonder whether this presents a unique opportunity to re-evaluate Pfizer's potential as a viable investment.
As of the second quarter of 2024, Pfizer has reported a slight revenue increase of 2.1% year-over-year for the first time since factors beyond COVID-19 sales began to overshadow the company’s financials. Interestingly, despite the ongoing decline in their COVID-19 product sales, the core business has seen a robust growth rate of 14%. The landscape is shifting, and the numbers support a closer look.
1) Pfizer’s Return to Revenue Growth
Despite the major downturn in COVID-19 product sales, with Q2 2024 showing Comirnaty revenues down by 87%, the overall earnings of Pfizer have begun to stabilize. Notably, the company’s total revenue at $13.28 billion surpassed expectations, showcasing resilience amidst challenging market conditions.
With earnings per share hitting 60 cents, which surpassed consensus estimates, Pfizer has managed to increase its gross margin and raise its full-year earnings guidance, showcasing positive momentum in the face of adversity.
2) An Impressive Drug Pipeline
One of Pfizer's strengths lies in its extensive drug pipeline, boasting 113 candidates under development, including several nearing completion for regulatory approval. The company, having increased its investment in oncology with notable acquisitions, is poised to reap the benefits of new drugs entering the market.
This year, Pfizer received full FDA approval for tivdak, expected to generate significant revenue. Additionally, their continued development of Danuglipron, a GLP-1 treatment aimed at weight management, is anticipated to become a valuable product with expected sales around $3 billion.
3) Investment Potential in Value Territory
Currently, Pfizer stock is trading at a forward earnings ratio of 10.74, significantly marking it as undervalued. With a hefty annual dividend of 5.88%, the stock offers attractive compensation to investors during these uncertain times.
The recent strategic decision to reduce its stake in consumer healthcare company Haleon further bolsters Pfizer’s cash reserves, bringing its total cash position above $10 billion. This financial strength opens doors for potential acquisitions or investments in innovation to drive further growth.
4) Analyzing Technical Aspects
The technical outlook of Pfizer’s stock seems promising as it forms a cup and handle pattern. This technical chart formation suggests that, upon breaking the $30.75 resistance, there could be a significant upward movement. The current support levels hold significance in guiding traders and investors in making informed decisions.
Furthermore, the consensus among analysts currently sets the average price target at $34.54, with bullish estimates going as high as $45, indicating market confidence in Pfizer's recovery and future growth potential.
Frequently Asked Questions
What factors led to the decline of Pfizer stock?
The decline in Pfizer stock was primarily due to a decrease in COVID-19 product sales as the pandemic subsided, leading to decreased revenues.
Is Pfizer's revenue growth sustainable?
Given the 14% revenue growth from non-COVID products and a strong drug pipeline, there are indications that Pfizer’s revenue growth may be sustainable moving forward.
What is the significance of Pfizer's drug pipeline?
Pfizer's drug pipeline consists of 113 candidates, with several nearing final approval, which is crucial for future revenue generation and market competitiveness.
How does Pfizer's current valuation impact investments?
The current valuation of Pfizer, trading at 10.74x forward earnings, suggests it is undervalued, presenting a buying opportunity for investors looking for value.
What is the technical outlook for Pfizer stock?
The formation of a cup and handle pattern in Pfizer’s stock suggests potential growth if it breaks past significant resistance levels, indicating possible bullish momentum.
